IRCT20230903059342N1招募中1 期
Phase 1 clinical trials of Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer
Kian Gen Azma Company0 个研究点目标入组 10 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Bladder Cancer has been confirmed.
- •The patient should be diagnosed by a urologist.
- •It is not possible to remove the bladder for the patient.
- •The age of the patient must be above 18 years
- •The patient should not be pregnant.
- •The patient's Karnofsky performance score (KPS) should be more than 50% (the patient is not disabled and does not need special assistance and care).
- •The ability to understand and sign the consent form including the patient and one of these cases: the patient's spouse, parent.
- •Ability to provide informed consent
- •Be willing to comply with all required protocol steps, including providing biological samples and returning to the clinical study site for subsequent visits.
- •Adequate performance status for treatment in the opinion of the enrolling urologist, including adequate hematological, liver, and renal function
- •Must be willing to use contraceptive methods during the study.
排除标准
- •Severe or life-threatening acute infection
- •A history of not following the doctor's treatment orders
- •Use of drugs that weaken the immune system
- •Having diseases that disrupt the immune system
- •History of organ transplantation
- •Allergy to measles vaccine
- •Concomitant use of other investigational treatments
- •Disease to other cancers such as skin that have not been fully treated.
研究者
相似试验
已完成
不适用
Phase I/IIa study of intravesical administration of 2-methyl-3-butenyl-1-pyrophosphate-stimulated gamma delta T cells in patients with non-invasive bladder cancer.on-invasive bladder cancerJPRN-UMIN000010942Tokyo Women's Medical University12
进行中（未招募）
1 期
Assessing the safety of atezolizumab being directly administered to the bladder in bladder cancer patients undergoing radical cystectomyrothelial cell carcinoma of the bladderCancerISRCTN15842444Sheffield Teaching Hospitals NHS Foundation Trust56
进行中（未招募）
不适用
Pilot Study of the Intravesical Administration of EOquin Immediately Following Transurethral Resection in Patients with Superficial Bladder Cancer. - Not applicableBladder Cancer Stage 1 without Cancer in SituPatients will have transitional-cell carcinoma of the bladder, clinical TNM stage Ta or T1 and histologic grade G1 or G2 before transurethral resection.MedDRA version: 9Level: PTClassification code 10005009EUCTR2006-002372-18-NLSpectrum Pharmaceuticals, Inc.20
招募中
1 期
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2High-risk Non-muscle Invasive Bladder CancerNCT06378242RemeGen Co., Ltd.24
已完成
3 期
Phase III trial of a single early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III)pper tract urothelial carcinomaJPRN-UMIN000024267Japan Clinical Oncology Group (JCOG)310